Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™) Accepted Abstract will Showcase Clinical Data on Investigational Drug Rhenium NanoLiposomes (RNL™)
See the article here:
ReSPECT Glioblastoma Clinical Trial Data to be Presented at 2020 Society for Neuro-Oncology Annual Meeting
CORAL GABLES, Fla., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), today reported that the federal judge handling Catalyst's case against the FDA has adopted the previously reported Report and Recommendation of the Magistrate Judge, granted summary judgment in favor of the FDA and Jacobus, and dismissed Catalyst's case. Catalyst is currently reviewing the District Judge's decision, which it believes to be erroneous, and intends to appeal the result to the Eleventh Circuit Court of Appeals.
Visit link:
Catalyst Pharmaceuticals Announces Ruling on Lawsuit against the FDA and Intent to Appeal
Mechelen, Belgium; 29 September 2020, 22.01 CET – Galapagos NV (Euronext & NASDAQ: GLPG) announces dosing of a first patient in their psoriasis trial, one of three patient trials currently recruiting to evaluate efficacy and safety of Toledo compound GLPG3970. Furthermore, Galapagos plans to unveil the novel Toledo target class and share GLPG3970 Phase 1 data at its inaugural Toledo Roundtable to be held virtually on 27 October 2020.
Original post:
Galapagos announces first dosing with Toledo compound GLPG3970 in psoriasis trial
STAMFORD, Conn., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, today announced the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020. Mr. Reilly will be responsible for overseeing the Company’s financial strategy and activities related to accounting, capital markets, and business operations. He joins Cara from Allergan, now part of AbbVie, where he served as Finance Head for the U.S. General Medicine Commercial Business.
Excerpt from:
Cara Therapeutics Appoints Thomas Reilly as Chief Financial Officer
Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer Mark Fitzpatrick to Step Down as President and Principal Financial Officer Following the Appointment of a New Chief Financial Officer
Go here to see the original:
Chiasma Announces Planned Transition of Former CEO
Company announcement no. 36 - 20 29 September 2020
Read more:
Transactions in connection with share buyback program
BASKING RIDGE, N.J., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that its Chief Executive Officer, David J. Mazzo, Ph.D., will present a company overview at the BIO Investor Forum, being held virtually on October 13-15, 2020. This presentation will be available on demand for BIO Investor attendees.
Original post:
Caladrius Biosciences to Present at the BIO Investor Forum Digital
BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, announced the appointment of Sachiyo Minegishi as chief financial officer, effective today. In addition, the company announced that Jennifer Wellman has been promoted to chief operating officer, from her prior role as senior vice president of regulatory and quality.
Read the rest here:
Akouos Announces Key Leadership Appointments
TORONTO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the “Company”) today announces changes to its Board of Directors and management team and a Company-wide operational update on its path to profitability.
Read the original:
Auxly Strengthens its Board and Announces Additional Steps on Path to Profitability
WILMINGTON, Del., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its initial public offering of 9,573,750 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 1,248,750 additional shares of common stock, at a public offering price of $19.00 per share. The aggregate gross proceeds to Prelude Therapeutics from the offering were approximately $181.9 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Prelude Therapeutics.
See the rest here:
Prelude Therapeutics Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares